References
Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum: applying current evidence to clinical practice. Cancer Treat Rev. 2012;38:397–406.
Ceelen W, Ramsay RG, Narasimhan V, Heriot AG, De Wever O. Targeting the tumor microenvironment in colorectal peritoneal metastases. Trends Cancer. 2020;6:236–46.
Klaver YLB, Simkens LHJ, Lemmens VEPP, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. EJSO Eur J Surg Oncol. 2012;38:617–23.
Kang YJ, O’Haire S, Franchini F, IJzerman M, Zalcberg J, Macrae F, et al. A scoping review and meta-analysis on the prevalence of pan-tumor biomarkers (dMMR, MSI, high TMB) in different solid tumors. Sci Rep. 2022;12:20495.
Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.
Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, et al. Clinical role of the TME in solid cancer. Br J Cancer. 2019;120:45–53.
Acknowledgment
This study was supported by the RAD project.
Author information
Authors and Affiliations
Contributions
All the authors listed have made a substantial, direct, and intellectual contribution to the work, especially in the comprehensive genetic and immunophenotypic analysis of CPMs from two treatment-naïve patients with MSS-CRC. Each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content, in accordance with the guidelines set by the International Committee of Medical Journal Editors (ICMJE).
Corresponding author
Ethics declarations
Disclosure
All authors declare that they have no competing interests, financial or otherwise, related to the current work. All the sources of funding for the research are disclosed, and any affiliations or involvement (either competitive or amiable) in any organization or entity with a direct financial interest in the subject matter or materials discussed in the manuscript are disclosed.
Consent to Publication
The submitted work is original and provides a comprehensive analysis of the genetic and immunophenotypic landscape of CPM in mCRC patients. It has not been published elsewhere and is not under consideration by any other publication. All data, figures, and tables are original, and any similarities with existing work are cited appropriately.
Ethical Approval
The research was conducted after IRB approval was obtained. All procedures involving analysis of patient specimens were performed in compliance with relevant laws and institutional guidelines. The study adhered to ethical guidelines, ensuring the confidentiality and rights of the patients involved.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Mirza, M.B., Smith, P.M., Wang, Y. et al. Intra-Patient Heterogeneity in Micro-satellite-stable Colorectal Metastases: Does Immunotherapy Have a Role in Colorectal Peritoneal Metastases?. Ann Surg Oncol 31, 1440–1443 (2024). https://doi.org/10.1245/s10434-023-14694-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-14694-8